WOAG
WITHDRAWAL OF ATTORNEY GRANTED
30/07/2026
Voltar para busca
Dado oficial do USPTO
HEMOTEQ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
HEMOTEQ
ST13
US500000076326915Classe
5, 10, 40, 42
Pedido
76326915
Registro
2931143
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
61
Atualização mais recente
31/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 40, 42
Data de depósito
18/10/2001
Data de registro
08/03/2005
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/02/2025
Última transação
31/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
2001-02-00
Primeiro uso no comércio
2001-02-00
Código do desenho
1
Tipo de titular
03
Localização do titular
WUERSELEN, DE
Examinador
WELLS, KELLEY L
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
HEMOTEQ AG
Hemoteq GmbH
Representantes
HEMOTEQ AG
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
heparin preparations and heparin derivatives combined with organic macromolecular substances with anti-thrombotic and/or anti-coagulative properties for use in coating artificial and natural surfaces for intracorporeal and extracorporeal circulation and for use in coating surgical implants; surgical implants comprising living tissue and organsheatsheart partslungsarteriesveinsaortas of mammalsespecially hearts of pigsheart valves of pigs and corpse veins; surgical implants comprising living tissue and organs coated with heparinheparin derivatives and macromolecular agentsheartsheart valveslungsarteriesveins and aortas of mammals * all goods exclusive of the use of antibodies *
Classe 10
surgical implants comprising artificial materialartificial heart valvesheartslungsarteriesveins and aortas; medical instruments and accessories for use with the transfer and handling of bloodtubingvalvescontainersplastic bagscansneedlescatheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation; surgical implants comprising artificial material; anti-thrombotic and/or anti-coagulative surgical implantsartificial surfacesartificial surfacesartificial heart valvesartificial heartsartificial lungsartificial arteriesartificial veinsartificial aortastubingvalvescontainersplastic bagscansneedlescathetersaccessories for use with the transfer and handling of blood for medical purposesespecially for intracorporeal and extracorporeal circulation; artificial surgical implants coated with heparinheparin derivatives and macromolecular agentsartificial heart valvesheartslungsarteriesveins and aortas; medical instruments and accessories for use with the transfer and handling of blood coated with heparinheparin derivatives and macromolecular agentstubingvalvescontainersplastic bagscansneedlescatheters and for use with artificial surgical implants for the cardiovascular system and for extracorporeal circulation * all goods exclusive of the use of antibodies *
Classe 40
Commissioned coating services of artificial surgical implants and of surgical implants comprised of living tissue and organs with biopolymersespecially with heparinheparin derivatives and anti-thrombotic and/or coagulative macromolecular substances * all coating services exclusive of the use of antibodies *
Classe 42
commissioned research and development services in the fields of surrogates for blood and blood substitutesblood productsblood-compatible materials and blood-compatible implants; commissioned research and development and consultation services in the fields of artificial surgical implants and of surgical implants comprised of living tissue and organs for the cardiovascular system and for extracorporeal circulationespecially coatings with heparinheparin derivatives and anti-thrombotic and/or anti-coagulative macromolecular substances; biochemicalpharmaceuticalmedical and scientific research services in the fields of surrogates for bloodblood substitutesblood productsblood-compatible materialblood-compatible implants and blood-compatible parts for the cardiovascular system and for extracorporeal circulation * all research and development services exclusive of the use of antibodies *
Publicações
Histórico de despachos e eventos da marca no USPTO.
61 publicações encontradas
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
30/07/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/07/2026
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
23/07/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/07/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/07/2026
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/02/2025
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
05/02/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/02/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/02/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
11/10/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
08/03/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2018
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
25/04/2015
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
25/04/2015
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
25/04/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
23/03/2015
E89R
TEAS SECTION 8 & 9 RECEIVED
06/03/2015
CANT
CANCELLATION TERMINATED NO. 999999
14/07/2011
CAND
CANCELLATION DENIED NO. 999999
14/07/2011
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
31/03/2011
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
31/03/2011
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
31/03/2011
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
18/03/2011
E815
TEAS SECTION 8 & 15 RECEIVED
04/03/2011
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
21/04/2010
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
23/03/2010
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
25/02/2010
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
24/02/2010
ES7R
TEAS SECTION 7 REQUEST RECEIVED
23/02/2010
PETC
CANCELLATION INSTITUTED NO. 999999
02/02/2009
R.PR
REGISTERED-PRINCIPAL REGISTER
08/03/2005
REGV
LAW OFFICE REGISTRATION REVIEW COMPLETED
22/10/2004
ALIE
ASSIGNED TO LIE
19/10/2004
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
13/10/2004
DOCK
ASSIGNED TO EXAMINER
13/10/2004
SUPC
STATEMENT OF USE PROCESSING COMPLETE
08/10/2004
IUAF
USE AMENDMENT FILED
24/09/2004
EISU
TEAS STATEMENT OF USE RECEIVED
24/09/2004
NOAM
NOA MAILED - SOU REQUIRED FROM APPLICANT
29/06/2004
PUBO
PUBLISHED FOR OPPOSITION
06/04/2004
EMRV
EMAIL RECEIVED
05/04/2004
NPUB
NOTICE OF PUBLICATION
17/03/2004
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/03/2004
44DD
SEC. 44(D) CLAIM DELETED
04/02/2004
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2004
CNSL
LETTER OF SUSPENSION MAILED
19/11/2003
DOCK
ASSIGNED TO EXAMINER
18/11/2003
PCRC
PETITION TO DIRECTOR RECEIVED
29/10/2003
PAPER RECEIVED
29/10/2003
CFIT
CASE FILE IN TICRS
18/10/2003
CFIT
CASE FILE IN TICRS
16/10/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/09/2003
PAPER RECEIVED
22/09/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/09/2003
CNSI
INQUIRY AS TO SUSPENSION MAILED
19/03/2003
CNSL
LETTER OF SUSPENSION MAILED
26/08/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/07/2002
PAPER RECEIVED
03/07/2002
CNRT
NON-FINAL ACTION MAILED
31/12/2001
DOCK
ASSIGNED TO EXAMINER
27/12/2001
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HEMOTEQ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.